AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 82 min read$BBIO

Kumar Neil sold $5.4M of BBIO (indirect holdings)

Kumar Neil (Chief Executive Officer) sold 80,000 indirectly-held shares of BridgeBio Pharma, Inc. (BBIO) at an average of $67.67 ($65.72–$68.96, $5.41M total) across 14 trades over 2026-06-04 to 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kumar Neil
Published Jun 8, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 10:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BBIO
Neutral
medium confidence
Mentioned
$BBIO
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIONeutralLow
01

Why it matters

The newest concrete fact is the CEO’s open-market sale totaling $5.41M across 80,000 shares, executed under a pre-arranged Rule 10b5-1 plan.

02

Market read

This provides fresh, primary-source information on insider activity, but the 10b5-1 structure typically limits interpretive impact.

03

What to watch

The filing shows indirect ownership and multiple small trades across two days; traders may focus on whether future filings show continued selling or a shift to buying.

Relevance 5/10Novelty 8/10Timing: Filed June 8, 2026 (covers sales June 4–5)

Background

The article is an SEC Form 4 insider transaction disclosure for BridgeBio Pharma, Inc. (BBIO).

Company-level read

Ticker impact

$BBIONeutralMedium confidence
Context

BridgeBio CEO Kumar Neil sold $5.41M of BBIO shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction may be muted given the pre-arranged nature.

Evidence & confidence

The filing is a primary-source Form 4 showing sale size ($5.41M) and that it was executed under a Rule 10b5-1 plan, which typically dampens interpretive value versus discretionary selling.

Market effects

Sector

No direct sector read-through; this is company-specific insider transaction disclosure.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because the trades were executed under a pre-arranged 10b5-1 plan, the sale may reflect routine liquidity planning rather than a change in fundamentals.

Key entities

  • issuer
    BridgeBio Pharma, Inc.

    Company whose shares were sold by its CEO under a 10b5-1 plan.

  • insider
    Kumar Neil

    CEO and director who sold 80,000 shares of BBIO for ~$5.41M.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BBIO insider trading history →

Related articles

OCT 19
$BBIOMed

BBIO Maintained by Piper Sandler -- Price Target Raised to $120

Piper Sandler maintained an Overweight rating on BridgeBio Pharma (BBIO) and raised its price target to $120 from $115, citing growth potential in the biotech sector. The company's GF Value™ suggests it is 59.4% undervalued, but its GF Score™ indicates moderate performance with strong growth but weak financial strength. Insider selling activity totaled $4.58M over the last three months.

gurufocus.com2 min
OCT 15
$BBIOMed

H.C. Wainwright reiterates Buy on BridgeBio stock, cites trial data

H.C. Wainwright reiterated a Buy rating and $120 price target for BridgeBio Pharma (BBIO) after positive Phase 3 trial data for encaleret. The stock trades near its fair value estimate, with a Strong Buy consensus and targets ranging from $80 to $156. BridgeBio also announced FDA acceptance of a New Drug Application for infigratinib, with a target action date in February 2027.

investing.com2 min
OCT 15
$BBIOMed

BridgeBio Pharma assumed with a Buy at UBS

UBS initiated coverage of BridgeBio Pharma (BBIO) with a Buy rating and a $92 price target, citing underestimation of its lead drug's potential. UBS projects 2035 sales of $4.1B, higher than the $3.7B consensus. The firm's optimism is based on a 50-doctor survey, comparative data, and recent real-world evidence.

tipranks.com2 min
OCT 13
$BBIOMedAI 8/10

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

BridgeBio Pharma, Inc. (BBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia - Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significa

SEC EDGAR 8-K2 min
OCT 12
$BBIOMedAI 8/10

BridgeBio Reports Encaleret Gains In ADH1; Starts RECLAIM-HP Phase 3 In Chronic Hypoparathyroidism

BridgeBio Pharma (BBIO) presented Phase 3 data for Encaleret in autosomal dominant hypocalcemia type 1, showing improved PTH levels and symptoms. The company also began a Phase 3 trial for chronic hypoparathyroidism. The FDA accepted its New Drug Application under Priority Review, with a target action date of May 8, 2027. BBIO shares closed at $65.35, up 0.48%.

rttnews.com2 min